Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.53 |
| ▸ | MMP13 | P45452 | 2/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15103494 | 0.89 | GPR119 (0.56) | GPR119MMP13 | |
| SCHEMBL22585205 | 0.86 | GPR119 (0.57) | GPR119MMP13 | |
| SCHEMBL30194693 | 0.86 | GPR119 (0.57) | GPR119MMP13 | |
| SCHEMBL22557687 | 0.84 | CNR2 (0.49) | — | |
| SCHEMBL17942389 | 0.84 | TGFBR1 (0.53) | GPR119 | |
| SCHEMBL10265584 | 0.83 | GPR119 (0.57) | GPR119MMP13 | |
| SCHEMBL17942537 | 0.82 | TGFBR1 (0.59) | GPR119MMP13 | |
| SCHEMBL7787125 | 0.82 | STS (0.58) | GPR119 | |
| SCHEMBL3034734 | 0.82 | GPR119 (0.56) | GPR119 | |
| SCHEMBL23329646 | 0.81 | STS (0.65) | GPR119MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162836-B2 | N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use | Modern Biosciences Limited (GB) | 2024-12-10 | — | — | US | disclosed |
| CN-113766953-B | N-acyl- {4- [ (4-aryl-phenyl) sulfonylmethyl ] piperidine } compounds and their therapeutic uses | 现代生物科学有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230022917-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | ISTESSO THERAPEUTICS LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-20230022917-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | ISTESSO THERAPEUTICS LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| CN-113766953-A | N-acyl- {4- [ (4-aryl-phenyl) sulfonylmethyl ] piperidine } compounds and their therapeutic use | 现代生物科学有限公司 | 2021-12-07 | — | — | CN | disclosed |
| WO-2020212581-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | Modern Biosciences Limited (GB) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162836-B2 | N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use | MCL1, BCL9, BCL9L | GPR119 629/4885MMP13 607/4885PTPN2 3399/4885 |
| US-20230022917-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | MCL1, BCL9, BCL9L | GPR119 629/4885MMP13 607/4885PTPN2 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.